309 related articles for article (PubMed ID: 23111165)
21. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
22. Pathology of combined hepatocellular-cholangiocarcinoma.
Yeh MM
J Gastroenterol Hepatol; 2010 Sep; 25(9):1485-92. PubMed ID: 20796144
[TBL] [Abstract][Full Text] [Related]
23. Histopathology of hepatocellular carcinoma.
Schlageter M; Terracciano LM; D'Angelo S; Sorrentino P
World J Gastroenterol; 2014 Nov; 20(43):15955-64. PubMed ID: 25473149
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of glypican-3, arginase-1 and hepatocyte paraffin antigen -1 in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
Wang C; Shao X; Zhang X; Xie C; Yu J; Xu X; Yang J; Li Y; Xu W
Transl Cancer Res; 2020 Jan; 9(1):128-136. PubMed ID: 35117166
[TBL] [Abstract][Full Text] [Related]
25. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas.
Okamura N; Yoshida M; Shibuya A; Sugiura H; Okayasu I; Ohbu M
Pathol Int; 2005 Nov; 55(11):724-31. PubMed ID: 16271085
[TBL] [Abstract][Full Text] [Related]
26. A subset of well-differentiated hepatocellular carcinomas are Arginase-1 negative.
Clark I; Shah SS; Moreira R; Graham RP; Wu TT; Torbenson MS; Chandan V
Hum Pathol; 2017 Nov; 69():90-95. PubMed ID: 28970136
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
28. Elevated expression of Bmi1 in hepatocellular carcinoma with bile duct tumor thrombi.
Zhang R; Xu LB; Zeng H; Yu XH; Wang J; Liu C
Hepatogastroenterology; 2013; 60(128):2042-7. PubMed ID: 24719948
[TBL] [Abstract][Full Text] [Related]
29. Combined hepatocellular and cholangiocarcinoma with marked squamous cell carcinoma components arising in non-cirrhotic liver.
Tsuneyama K; Kaizaki Y; Doden K; Kidani E; Harada K; Sasaki M; Nakanuma Y
Pathol Int; 2003 Feb; 53(2):90-7. PubMed ID: 12588436
[TBL] [Abstract][Full Text] [Related]
30. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.
Fu X; Tan L; Liu S; Li H; Chen L; Qin J; Wu M; Wang H
J Cancer Res Clin Oncol; 2004 Sep; 130(9):514-20. PubMed ID: 15221469
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte paraffin 1 and arginase-1 are effective panel of markers in HBV-related HCC diagnosis in fine-needle aspiration specimens.
Moudi B; Mahmoudzadeh-Sagheb H; Heidari Z
BMC Res Notes; 2020 Aug; 13(1):388. PubMed ID: 32854754
[TBL] [Abstract][Full Text] [Related]
32. Combined hepatocellular-cholangiocarcinoma. Cytologic findings in four cases.
Dusenbery D
Acta Cytol; 1997; 41(3):903-9. PubMed ID: 9167724
[TBL] [Abstract][Full Text] [Related]
33. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology.
McKnight R; Nassar A; Cohen C; Siddiqui MT
Cancer Cytopathol; 2012 Aug; 120(4):223-9. PubMed ID: 22298472
[TBL] [Abstract][Full Text] [Related]
34. Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Terada T; Matsunaga Y
J Hepatol; 2000 Dec; 33(6):961-6. PubMed ID: 11131459
[TBL] [Abstract][Full Text] [Related]
35. S-100-positive nerve fibers in hepatocellular carcinoma and intrahepatic cholangiocarcinoma: an immunohistochemical study.
Terada T; Matsunaga Y
Pathol Int; 2001 Feb; 51(2):89-93. PubMed ID: 11169146
[TBL] [Abstract][Full Text] [Related]
36. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies.
Fujiwara M; Kwok S; Yano H; Pai RK
Cancer Cytopathol; 2012 Aug; 120(4):230-7. PubMed ID: 22434791
[TBL] [Abstract][Full Text] [Related]
37. Hepatocyte paraffin-1, CD10, and CD34 immunostaining as a diagnostic aid in cytologic diagnosis of hepatic cancer.
Agarwal A; Handa U; Kundu R; Sachdev A; Kochhar S
J Cancer Res Ther; 2022 Dec; 18(Supplement):S434-S438. PubMed ID: 36510999
[TBL] [Abstract][Full Text] [Related]
38. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.
Hanif R; Mansoor S
J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115
[TBL] [Abstract][Full Text] [Related]
39. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
Lau SK; Prakash S; Geller SA; Alsabeh R
Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785
[TBL] [Abstract][Full Text] [Related]
40. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]